Overview
Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs generally target specific subsets of cancer, and we aim to simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, Clovis has the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. We believe this approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy. Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision. Clovis Oncology is headquartered in Boulder, Colorado. Please visit www.clovisoncology.com for more information, including additional office locations in the U.S. and Europe. Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments. Clovis Oncology, Inc. operates as a biotechnology company. The Company focuses on acquiring, developing, and commercializing of cancer treatments. Clovis Oncology serves clients worldwide. Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. Clovis Oncology a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. Clovis targets its development programs for the treatment of specific subsets of cancer populations, and seeks to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients that are most likely to benefit from their use. The Company is currently developing three product candidates for which they hold global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine, which is in a pivotal study in a specific patient population for the treatment of metastatic pancreatic cancer; CO-1686, a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), and Rucaparib, an orally available, small molecule poly (ADP-ribose) polymerase, or PARP, inhibitor being developed for various solid tumors that is currently in a Phase I clinical trial. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and . Clovis Oncology isn't trying to treat all cancers, just a few very specific ones. The biopharmaceutical company acquires, develops, and commercializes therapies for subsets of ovarian, lung, and other cancers that don't respond well to existing commercial drugs. Its first marketed product is Rubraca, which is approved in the US for the treatment of ovarian cancer. The company has additional candidates in its pipeline including oral treatments for ovarian solid tumors as well as a drug for gastrointestinal cancer. Clovis also works with partners to develop companion diagnostics for its treatment drugs. Try D&B Hoovers Free Clovis Oncology isn't trying to treat all cancers, just a few very specific ones. The biopharmaceutical company acquires, develops, and commercializes therapies for subsets of ovarian, lung, and other cancers that don't respond well to existing commercial drugs. Its first marketed product is Rubraca, which is approved in the US for the treatment of ovarian cancer. The company has additional candidates in its pipeline including oral treatments for ovarian solid tumors as well as a drug for gastrointestinal cancer. Clovis also works with partners to develop companion diagnostics for its treatment drugs.
